Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SEC-Like Agency Would Bring Transparency To Healthcare – Herzlinger

This article was originally published in The Gray Sheet

Executive Summary

Harvard Business School Professor Regina Herzlinger advocates a Securities and Exchange Commission-style agency to foster price and outcomes transparency within healthcare

You may also be interested in...



Hospital price data published

CMS posts payment information on its website for the 30 most common elective procedures and reasons for admissions, including implantation of defibrillators and hip and knee replacements. Posted June 1 to kick off the agency's transparency initiative, the data shows the service volumes and Medicare payment ranges for all hospitals by county to help consumers compare price and quality of care (1"The Gray Sheet" March 20, 2006, p. 13). The agency plans to add geographically based payment information for ambulatory surgery centers this summer, and outpatient and physician services in the fall...

Device Industry Aims To Prevent Image Problems That Have Plagued Pharma

Recent polling data commissioned by AdvaMed suggest that medical devices, if not the industry itself, are still in relative good graces with the public, but that clear vulnerabilities exist

Pooled Procurement Of Cancer Drugs In India: Is Pharma Game For More?

India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel